This presentation continues a series on EBM to discuss issues relating to the critical appraisal of the literature.
2 years ago we discussed the principles underlying sur-
vival analysis. This presentation is a follow-up focusing on
‘drug survival’ studies. ‘Drug survival’ studies are increas- ingly common papers in the literature, mainly due to the increasing number of biologic agents available to treat psoriasis. ‘Drug survival’ studies use survival analysis to compare different biologics agents, in what has been called a ‘real world’ scenario. This presentation will dis- cuss the underlying assumptions and methodology behind
‘drug survival’ studies.